𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Successful application of pentoxifylline in the treatment of HTLV-I associated myelopathy

✍ Scribed by Susumu Shirabe; Tatsufumi Nakamura; Akira Tsujino; Yoshihiro Nishiura; Takafumi Furuya; Hirofumi Goto; Akihito Suenaga; Shunya Nakane; Toshiro Yoshimura; Shigenobu Nagataki

Book ID
119468615
Publisher
Elsevier Science
Year
1997
Tongue
English
Weight
56 KB
Volume
151
Category
Article
ISSN
0022-510X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Increased replication of HTLV-I in HTLV-
Increased replication of HTLV-I in HTLV-I–associated myelopathy
✍ Dr Mitsuaki Yoshida; Mitsuhiro Osame; Hisaomi Kawai; Masami Toita; Nanako Kuwasa πŸ“‚ Article πŸ“… 1989 πŸ› John Wiley and Sons 🌐 English βš– 474 KB πŸ‘ 2 views

To estimate the replication of the human T-cell leukemia virus type I (HTLV-I) in patients with HTLV-I-associated myelopathy (HAM), or tropical spastic paraparesis (TSP), HTLV-I DNA integrated into lymphocyte genomes was analyzed by Southern blot hybridization. HTLV-I DNA was detected in 125 (82%) o

Parkinsonism in the course of HTLV-I-ass
Parkinsonism in the course of HTLV-I-associated myelopathy
✍ Marzia Puccioni-Sohler; Regina Papais-Alvarenga; Priscila Mesquita de Souza; Sil πŸ“‚ Article πŸ“… 2005 πŸ› John Wiley and Sons 🌐 English βš– 55 KB

## Abstract Parkinsonian syndromes may represent a complication of viral infection. Human T cell lymphotropic virus I (HTLV‐I) is a cause of a chronic myelopathy in which encephalic involvement has been also found. We report on the case of a 60‐year‐old man with HTLV‐I‐associated myelopathy, compli

Treatment of HTLV-I-associated myelopath
Treatment of HTLV-I-associated myelopathy with high-dose intravenous gammaglobulin
✍ Y. Kuroda; H. Takashima; A. Ikeda; C. Endo; R. Neshige; R. Kakigi; H. Shibasaki πŸ“‚ Article πŸ“… 1991 πŸ› Springer 🌐 English βš– 525 KB

Fourteen patients with HTLV-1-associated myelopathy were treated with high-dose intravenous gammaglobulin (IVGG). Ten received 10 g/day of IVGG and 4 received 400 mg/kg of body-weight/day of IVGG for 5 consecutive days. Improvement of spastic paraparesis was observed in 10 within 7 days of the comme